Baseline total metabolic tumor volume is prognostic for refractoriness to Iimunochemotherapy in DLBCL: results from GOYA
Introduction A good response to initial therapy is key to maximizing survival in patients with diffuse large B-cell lymphoma (DLBCL), but patients with chemorefractory disease and early progression have poor outcomes. Patients and Methods Data from the GOYA study in patients with DLBCL who received...
| Autores: | , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Universidad de Navarra |
| Repositorio: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Idioma: | inglés |
| OAI Identifier: | oai:dadun.unav.edu:10171/66123 |
| Acceso en línea: | https://hdl.handle.net/10171/66123 |
| Access Level: | acceso abierto |
| Palabra clave: | Lymphoid malignancies Primary chemorefractory disease Prognostic indicators Early relapse Overall survival Unidad de Investigación clínica |
| id |
ES_3be16aa4f4a5fbae21dcd7cda145c3da |
|---|---|
| oai_identifier_str |
oai:dadun.unav.edu:10171/66123 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Baseline total metabolic tumor volume is prognostic for refractoriness to Iimunochemotherapy in DLBCL: results from GOYACanales-Ruiz, I. (Irene)|||/items/a90dde96-9ef9-4994-8840-851258793345Martelli, M. (Mauricio)|||/items/a6d679d0-6c63-4e20-8236-e3483db90b03Sehn, L.H. (Laura H.)|||/items/8c73dec6-a8b0-48d9-bdfe-c29f6c78affbVitolo, U. (Umberto)|||/items/8335cc7b-e868-44e3-8c75-27c5f7f78d18Nielsen, T.G. (Tina G.)|||/items/4cca2474-652c-41e4-8725-0f55b404d1f9Sellam, G. (Gilla)|||/items/2c37a1d4-1e88-44c7-aa6f-87899e3775ffBottos, A. (Alessia)|||/items/7afca8ed-325b-4868-a036-15c75e312526Klingbiel, D. (Dirk)|||/items/b0e08286-dfa8-454a-b04d-3fc01634368aKostakoglu, L. (Lale)|||/items/81de2cb9-9f5a-4251-8999-5c269eba5523Lymphoid malignanciesPrimary chemorefractory diseasePrognostic indicatorsEarly relapseOverall survivalUnidad de Investigación clínicaIntroduction A good response to initial therapy is key to maximizing survival in patients with diffuse large B-cell lymphoma (DLBCL), but patients with chemorefractory disease and early progression have poor outcomes. Patients and Methods Data from the GOYA study in patients with DLBCL who received first-line rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) were analyzed. Positron emission tomography/computed tomography (PET/CT)-derived characteristics associated with total metabolic tumor volume (TMTV) and clinical risk factors for primary chemorefractory disease and disease progression within 12 months (POD12) were explored. Results Of those patients fulfilling the criteria for analysis, 108/1126 (10%) were primary chemorefractory and 147/1106 (13%) had POD12. Primary chemorefractory and POD12 status were strongly associated with reduced overall survival. After multivariable analysis of clinical and imaging-based risk factors by backward elimination, only very high TMTV (quartile [Q] 1 vs. Q4 odds ratio [OR]: 0.45; P = .006) and serum albumin levels (low vs. normal OR of 1.86; P = .004) were associated with primary chemorefractoriness. After additionally accounting for BCL2/MYC translocation in a subset of patients, TMTV and BCL2/MYC double-hit status remained as significant predictors of primary chemorefractoriness (Q1 vs. Q4 OR: 0.32, P = .01 and double-hit vs. no-hit OR of 4.47, P = .02, respectively). Risk factors including very high TMTV, high sum of the product of the longest diameters (SPD), geographic region (Asia), short time since diagnosis, extranodal involvement and low serum albumin were retained for POD12. Conclusion PET-derived TMTV has prognostic value in identifying patients at risk of early treatment failure.Dadun. Depósito Académico Digital Universidad de Navarra20232023-04-2720222022-01-0120222022-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/66123reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/661232026-06-21T12:47:57Z |
| dc.title.none.fl_str_mv |
Baseline total metabolic tumor volume is prognostic for refractoriness to Iimunochemotherapy in DLBCL: results from GOYA |
| title |
Baseline total metabolic tumor volume is prognostic for refractoriness to Iimunochemotherapy in DLBCL: results from GOYA |
| spellingShingle |
Baseline total metabolic tumor volume is prognostic for refractoriness to Iimunochemotherapy in DLBCL: results from GOYA Canales-Ruiz, I. (Irene)|||/items/a90dde96-9ef9-4994-8840-851258793345 Lymphoid malignancies Primary chemorefractory disease Prognostic indicators Early relapse Overall survival Unidad de Investigación clínica |
| title_short |
Baseline total metabolic tumor volume is prognostic for refractoriness to Iimunochemotherapy in DLBCL: results from GOYA |
| title_full |
Baseline total metabolic tumor volume is prognostic for refractoriness to Iimunochemotherapy in DLBCL: results from GOYA |
| title_fullStr |
Baseline total metabolic tumor volume is prognostic for refractoriness to Iimunochemotherapy in DLBCL: results from GOYA |
| title_full_unstemmed |
Baseline total metabolic tumor volume is prognostic for refractoriness to Iimunochemotherapy in DLBCL: results from GOYA |
| title_sort |
Baseline total metabolic tumor volume is prognostic for refractoriness to Iimunochemotherapy in DLBCL: results from GOYA |
| dc.creator.none.fl_str_mv |
Canales-Ruiz, I. (Irene)|||/items/a90dde96-9ef9-4994-8840-851258793345 Martelli, M. (Mauricio)|||/items/a6d679d0-6c63-4e20-8236-e3483db90b03 Sehn, L.H. (Laura H.)|||/items/8c73dec6-a8b0-48d9-bdfe-c29f6c78affb Vitolo, U. (Umberto)|||/items/8335cc7b-e868-44e3-8c75-27c5f7f78d18 Nielsen, T.G. (Tina G.)|||/items/4cca2474-652c-41e4-8725-0f55b404d1f9 Sellam, G. (Gilla)|||/items/2c37a1d4-1e88-44c7-aa6f-87899e3775ff Bottos, A. (Alessia)|||/items/7afca8ed-325b-4868-a036-15c75e312526 Klingbiel, D. (Dirk)|||/items/b0e08286-dfa8-454a-b04d-3fc01634368a Kostakoglu, L. (Lale)|||/items/81de2cb9-9f5a-4251-8999-5c269eba5523 |
| author |
Canales-Ruiz, I. (Irene)|||/items/a90dde96-9ef9-4994-8840-851258793345 |
| author_facet |
Canales-Ruiz, I. (Irene)|||/items/a90dde96-9ef9-4994-8840-851258793345 Martelli, M. (Mauricio)|||/items/a6d679d0-6c63-4e20-8236-e3483db90b03 Sehn, L.H. (Laura H.)|||/items/8c73dec6-a8b0-48d9-bdfe-c29f6c78affb Vitolo, U. (Umberto)|||/items/8335cc7b-e868-44e3-8c75-27c5f7f78d18 Nielsen, T.G. (Tina G.)|||/items/4cca2474-652c-41e4-8725-0f55b404d1f9 Sellam, G. (Gilla)|||/items/2c37a1d4-1e88-44c7-aa6f-87899e3775ff Bottos, A. (Alessia)|||/items/7afca8ed-325b-4868-a036-15c75e312526 Klingbiel, D. (Dirk)|||/items/b0e08286-dfa8-454a-b04d-3fc01634368a Kostakoglu, L. (Lale)|||/items/81de2cb9-9f5a-4251-8999-5c269eba5523 |
| author_role |
author |
| author2 |
Martelli, M. (Mauricio)|||/items/a6d679d0-6c63-4e20-8236-e3483db90b03 Sehn, L.H. (Laura H.)|||/items/8c73dec6-a8b0-48d9-bdfe-c29f6c78affb Vitolo, U. (Umberto)|||/items/8335cc7b-e868-44e3-8c75-27c5f7f78d18 Nielsen, T.G. (Tina G.)|||/items/4cca2474-652c-41e4-8725-0f55b404d1f9 Sellam, G. (Gilla)|||/items/2c37a1d4-1e88-44c7-aa6f-87899e3775ff Bottos, A. (Alessia)|||/items/7afca8ed-325b-4868-a036-15c75e312526 Klingbiel, D. (Dirk)|||/items/b0e08286-dfa8-454a-b04d-3fc01634368a Kostakoglu, L. (Lale)|||/items/81de2cb9-9f5a-4251-8999-5c269eba5523 |
| author2_role |
author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Dadun. Depósito Académico Digital Universidad de Navarra |
| dc.subject.none.fl_str_mv |
Lymphoid malignancies Primary chemorefractory disease Prognostic indicators Early relapse Overall survival Unidad de Investigación clínica |
| topic |
Lymphoid malignancies Primary chemorefractory disease Prognostic indicators Early relapse Overall survival Unidad de Investigación clínica |
| description |
Introduction A good response to initial therapy is key to maximizing survival in patients with diffuse large B-cell lymphoma (DLBCL), but patients with chemorefractory disease and early progression have poor outcomes. Patients and Methods Data from the GOYA study in patients with DLBCL who received first-line rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) were analyzed. Positron emission tomography/computed tomography (PET/CT)-derived characteristics associated with total metabolic tumor volume (TMTV) and clinical risk factors for primary chemorefractory disease and disease progression within 12 months (POD12) were explored. Results Of those patients fulfilling the criteria for analysis, 108/1126 (10%) were primary chemorefractory and 147/1106 (13%) had POD12. Primary chemorefractory and POD12 status were strongly associated with reduced overall survival. After multivariable analysis of clinical and imaging-based risk factors by backward elimination, only very high TMTV (quartile [Q] 1 vs. Q4 odds ratio [OR]: 0.45; P = .006) and serum albumin levels (low vs. normal OR of 1.86; P = .004) were associated with primary chemorefractoriness. After additionally accounting for BCL2/MYC translocation in a subset of patients, TMTV and BCL2/MYC double-hit status remained as significant predictors of primary chemorefractoriness (Q1 vs. Q4 OR: 0.32, P = .01 and double-hit vs. no-hit OR of 4.47, P = .02, respectively). Risk factors including very high TMTV, high sum of the product of the longest diameters (SPD), geographic region (Asia), short time since diagnosis, extranodal involvement and low serum albumin were retained for POD12. Conclusion PET-derived TMTV has prognostic value in identifying patients at risk of early treatment failure. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022 2022-01-01 2022 2022-01-01 2023 2023-04-27 |
| dc.type.none.fl_str_mv |
journal article http://purl.org/coar/resource_type/c_6501 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/10171/66123 |
| url |
https://hdl.handle.net/10171/66123 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra |
| instname_str |
Universidad de Navarra |
| reponame_str |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| collection |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869406334183538688 |
| score |
15,300719 |